Dr. Reddy's Laboratories Ltd
RDY Healthcare Drug Manufacturers Specialty & Generic
Dr. Reddy's Laboratories Ltd’s revenue for fiscal 2026 (year ended March 2026) was $3.6 billion, down 6.06% from fiscal 2025. In the quarter to June 2026, revenue fell 14.4%, EPS fell 70.0%, free cash flow fell 143.4% and total debt rose 34.0%, each against the same quarter a year earlier.
Follow RDY
Dr. Reddy's Laboratories Ltd (RDY) P/E ratio
As of 16 October 2026, Dr. Reddy's Laboratories Ltd (RDY) trades at a P/E ratio of 32.9×. Over the past ten years it has ranged from 15.9× (October 2019) to 58.5× (December 2020); the current reading is higher than 71% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 19.2× and above the Healthcare sector median of 23.0×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2026 | 25.8× | 29.03% |
| FY2025 | 20.0× | 9.18% |
| FY2024 | 18.3× | 7.03% |
| FY2023 | 17.1× | (42.77%) |
| FY2022 | 29.9× | (30.57%) |
| FY2021 | 43.0× | 74.94% |
| FY2020 | 24.6× | (2.31%) |
| FY2019 | 25.2× | (28.48%) |
| FY2018 | 35.2× | (4.39%) |
| FY2017 | 36.8× | 42.86% |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 36.5× | 41.51% |
| Mar 2026 | 25.8× | 41.42% |
| Dec 2025 | 18.2× | 5.65% |
| Sep 2025 | 17.3× | (24.21%) |
| 42 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| HIMS Hims & Hers Health, Inc. compare | n/m |
| VTRS Viatris Inc. compare | n/m |
| ELAN Elanco Animal Health Incorporated compare | n/m |
| NBIX Neurocrine Biosciences, Inc. compare | 19.2× |
| LNTH Lantheus Holdings, Inc. compare | 23.7× |
| RDY Dr. Reddy's Laboratories Ltd | 32.9× |
| AMRX AMNEAL PHARMACEUTICALS, INC. compare | 38.4× |
| KNSA Kiniksa Pharmaceuticals International, plc compare | 73.4× |
| ALKS Alkermes plc compare | 102× |
| Drug Manufacturers Specialty & Generic industry median | 19.2× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)